CPC A61K 47/32 (2013.01) [A61K 8/8188 (2013.01); A61K 9/0056 (2013.01); A61K 9/2027 (2013.01); A61K 9/4866 (2013.01); A61K 31/27 (2013.01); A61K 31/4178 (2013.01); A61Q 11/00 (2013.01); A61K 9/2054 (2013.01); A61K 31/325 (2013.01); A61K 31/4164 (2013.01); A61K 31/439 (2013.01); A61K 2300/00 (2013.01); A61P 1/00 (2018.01); A61P 37/00 (2018.01)] | 24 Claims |
1. A composition comprising:
a therapeutically acceptable dose of an active agent for once a day delivery of the active pharmaceutical compound in an amount effective to treat at least one of: Sjogren's syndrome, Xerostomia, dry mouth, hypo-salivation, or dental carries due to reduced or compromised salivation, wherein the active agent is at least one of Cevimeline, Pilocarpine, or Bethanechol, and is in an active pharmaceutical compound-resin complex that comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated for modified release coating, wherein the composition has an in vivo fasted serum profile with a first and a second peak, wherein the first peak occurs before 3 hours after ingestion and the second peak occurs after 3 hours after ingestion, wherein both the first and second peaks and 8 hours blood level concentrations are effective to increase salivation.
|